Patients may enroll with lower hematologic values, if bone marrow involvement is documented; in this case, patients should be transfused to hemoglobin >= 8 g/dL
Hemoglobin >= 9 g/dL (may have been transfused)
Hemoglobin concentration >= 8 g/dL (may be transfused)
Hemoglobin >= 9 g/dl (patients may be transfused to this level)
INCLUSION - PROCUREMENT: Hemoglobin (Hgb) > 8.0 (can be transfused)
Hemoglobin >= 8.0 g/dl (may be transfused) within 14 days of enrollment to trial
Patients who are unwilling to be transfused with blood components
INCLUSION - INFUSION: Hemoglobin (Hgb) > 8.0 (may be a transfused value)
PROCUREMENT INCLUSION: Hemoglobin (Hgb) > 8.0 (may be a transfused value)
Hemoglobin (Hgb) > 8.0 g/dL (can be transfused)
Hemoglobin ?9 g/dL (transfused Hgb allowed)
Hemoglobin (Hgb) > 8.0 g/dL (can be transfused)
Hemoglobin > 9 g/dL; patients may be transfused or receive erythropoietic treatment to meet this criterion
ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Hemoglobin (Hgb) > 8.0 (may be a transfused value)
Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
Hemoglobin (Hgb) > 8.0 (can be transfused)
TREATMENT WITH SJCAR19: Hemoglobin > 8 g/dl (can be transfused)
Hemoglobin >= 9/g/dL (may have been transfused).
Hemoglobin: >= 8 g/dL (may be transfused)
Hemoglobin > 8 g/dL; patients may be transfused to achieve this value; elevated indirect bilirubin due to post transfusion hemolysis is allowed
Hemoglobin ? 9 g/dL (may have been transfused)
Hemoglobin >= 9 g/dl (patients may be transfused to this level).
Hemoglobin >= 9.0 g/dL within 14 days of study registration. Patients must not be transfused for at least 14 days prior to study entry.
Patients who are unwilling to be transfused with blood components
Within 14 days of the first dose of study drug: Hemoglobin (Hgb) > 9.0 g/dL (may be transfused or receive epoetin alfa [e.g., Epogen] to maintain or exceed this level)
Hemoglobin < 9.0 g/dL (patients may be transfused above this threshold)
Hemoglobin ? 9 g/dL (may have been transfused)
Within 14 days of the first study treatment: Hemoglobin >= 9 g/dL (may have been transfused)
Hemoglobin >= 9 g/dL (may have been transfused)
Hemoglobin >= 9 g/dL (may have been transfused)
Hemoglobin > 8 g/dL; patients may be transfused to receive this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed
Hemoglobin >= 9/g/dL (may have been transfused)
Hemoglobin: >= 8 g/dL (may be transfused)
Within 14 days prior to registration: Hemoglobin (Hb) > 10.0 g/dL (can be transfused to this level)
Hemoglobin >= 9.0 g/dL (patients may be transfused to meet this criterion)
Hgb ?10 g/dL - can be transfused
Plts ? 75,000 - cannot be transfused (must be ? 7 days from last plt transfusion)
Hemoglobin < 9.0 g/dL; patients may not be transfused to meet enrollment criteria
Hemoglobin > 8 g/dl (may be transfused)
Platelets >= 100,000/mm^3 (may not be transfused to meet this level for enrollment)
Hemoglobin (Hgb) > 8.0 (may be transfused).
Hemoglobin (Hgb) > 9.0 g/dL (may be transfused or receive epoetin alfa [e.g., Epogen] to maintain or exceed this level) within 14 days of the first dose of study drug
Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)
Hemoglobin >= 9 g/dl (patients may be transfused to this level)
Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)
Hemoglobin >= 9 g/dL (may be transfused to maintain or exceed this level)
Hemoglobin > 8 g/dl (may be transfused)
Hemoglobin (Hgb) > 8.0 (may be a transfused value)
Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)
Hemoglobin > 8 g/dl (may be transfused)
Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)
Hemoglobin >= 8 g/dL; patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed (repeat if more than 3 days before the first dose)
Hemoglobin ? (9.0 g/dL) - patients may be transfused to meet this criterion.
Hemoglobin > 8 g/dL; patients may be transfused to achieve this value
Hemoglobin >= 9 g/dL (may be transfused to maintain or exceed this level)
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L; patients with documented marrow involvement may be transfused to this value, performed within 10 days of treatment initiation
Hemoglobin >= 9.0 g/dL (patients may be transfused to meet hemoglobin [Hgb] requirement)
Hemoglobin >= 8 g/dl (may be transfused)
Hemoglobin >= 10 g/dL (may be transfused but must be stable without clinical evidence of ongoing blood loss or hemolysis)
Willingness to be transfused to treat low hemoglobin levels
Hemoglobin >= 90 g/L (patients may be transfused to meet this criterion), obtained within 14 days prior to initiation of study treatment
Hemoglobin >8 g/dL. Participants may be transfused to achieve this value. Elevated indirect bilirubin due to post transfusion hemolysis is allowed.
Hemoglobin ? 8 g/dL (may be transfused ? 5 days)
Hemoglobin >= 9 g/dL (patients may be transfused to meet this requirement)
Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
Hemoglobin >9 g/dL (Subjects are allowed to be transfused to this level)
AT THE TIME OF INFUSION: Hemoglobin (Hgb) > 8.0g/dl (can be transfused)
Hemoglobin < 9 g/dl; patients may be transfused to maintain hemoglobin values > 9 g/dl
Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
Anticipated to be transfused at least 8 times annually during the study
Hemoglobin greater than 10 g/dl (patients may be transfused to achieve this hemoglobin)
Hemoglobin >= 9.0 g/dL (patients may be transfused to meet this criterion)
Unwilling to be transfused with blood components.
Hemoglobin: >= 8 g/dL (may be transfused)
Hemoglobin >= 9 g/dL; patients may be transfused to obtain a hemoglobin of >= 9 g/Dl
Hemoglobin (HgB)>8.0 (may be transfused)
Hemoglobin >= 9.0 g/dL (patients may be transfused to meet this criterion)
Subject has been transfused within the past 14 days
Hemoglobin >= 9 g/dL (>= 80 g/L; may be transfused)
Hemoglobin >= 9 g/dL (patients may be transfused to meet this criterion) (obtained within 28 days prior to the first study treatment)
Hemoglobin >= 9.0 g/dL\r\n* Patients may be transfused or receive erythropoietic treatment to meet this criterion
Platelet count >= 100 x 10^9/L (may have been transfused)
Hemoglobin ?9.0 g/dL (may have been transfused)